Background Lung cancer remains the leading cause of cancer-related deaths worldwide, with increasing attention being given to novel therapeutic strategies that target the mechanisms underlying tumor growth and drug resistance. Among these, ferroptosis, a regulated cell death driven by iron-dependent lipid peroxidation, has become a key focus in cancer research. Despite extensive research, the exact role of ferroptosis in lung cancer progression and treatment remains unclear, especially regarding its interaction with immune cells and the tumor microenvironment. Objective and methods To address these limitations, this study utilizes a comprehensive bibliometric analysis to explore the current landscape of ferroptosis research in lung cancer. We collected data from the Web of Science Core Collection, covering articles published between 2015 and 2025, and analyzed them using advanced tools such as VOSviewer and CiteSpace. Results This study uses a comprehensive bibliometric analysis to uncover key trends and emerging areas related to lung cancer in ferroptosis research. Recently, the focus has shifted from basic mechanisms to clinical applications, particularly in developing GPX4-targeted therapies and combination treatments. With increasing international collaboration, the United States and China have become key players. Interdisciplinary research, especially on ferroptosis and the cancer-immune system, offers new insights into its role in the tumor microenvironment and immunotherapy. Ferroptosis shows excellent promise in overcoming drug resistance by regulating iron-dependent lipid peroxidation and enhancing treatment efficacy. Future research should focus on ferroptosis’ clinical translation, particularly in personalized medicine and overcoming resistance, offering broad prospects for lung cancer treatment. Conclusion This paper provides valuable insights into the trends, key contributors, and emerging frontiers of ferroptosis research in lung cancer. It identifies important developments that can serve as a foundation for translating ferroptosis-based therapies into clinical practice, particularly to address drug resistance in lung cancer.
Background and objective: MicroRNAs (miRNAs) are implicated in cancer by exerting roles in tumor growth, metastasis, and even drug resistance. The general trends of miRNA research in diverse cancers are not fully understood. In this work, miRNA-related research in colorectal cancer, prostate cancer, leukemia, and brain tumors was analyzed in search of key research trends with clinical potential.Methods: A bibliometric analysis of articles, spanning from 2014 to 2024, was carried out with the major focus laid on four types of cancers. The Co-citation network analysis, keyword bursts, and the collaborative pattern were done in VOSviewer and CiteSpace, respectively.Results: Colorectal cancer had the highest publication volume, with research primarily focusing on gene expression, extracellular vesicles, and non-coding RNAs. Prostate cancer showed a shift toward clinical applications, while leukemia and brain tumor research, though less extensive, highlighted miRNA’s potential in early diagnosis and treatment. Co-citation analysis identified emerging research collaborations and key contributors.Conclusion: miRNA plays a pivotal role in cancer diagnosis, biomarker development, and therapeutic interventions. With advancements in non-invasive diagnostics and personalized medicine, miRNA offers significant potential for clinical applications. Future research should focus on miRNA’s role in drug resistance and combination therapies to accelerate its clinical translation.
26 January 2026 in Computational Biology and Chemistry